BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Braintree Laboratories

Criteria

Inclusion Criteria:

• Males or females 12 to 45 years of age with facial acne vulgaris

• Qualifying Investigator's Global Assessment severity score

• Qualifying number of non-inflammatory lesions

• Qualifying number of inflammatory lesions

Exclusion Criteria:

• Facial hair (beard), excessive scarring, sunburn or other disfigurement that may obscure the accurate assessment of acne grade

• Using medications that are reported to exacerbate acne

• Any clinically relevant finding at their baseline physical examination or dermatological medical history such as severe systemic diseases or diseases of the facial skin

• Have a known hypersensitivity or previous allergic reaction to any of the components

• Patients who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days

• Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures